Hudson Bay Capital Management
AVDL

Hudson Bay Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Hudson Bay Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-782,239
Closed -$16.9M – 1399
2025
Q4 		$16.9M Buy
+782,239
New +$15.2M 0.06% 246
2024
Q3 		– Sell
-522,277
Closed -$7.34M – 863
2024
Q2 		$7.34M Buy
522,277
+273,117
+110% +$4.45M 0.03% 298
2024
Q1 		$4.21M Buy
+249,160
New +$3.71M 0.02% 334

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Hudson Bay Capital Management's AVDL Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 782,239 shares — an estimated $16.9M sold.

Hudson Bay Capital Management first reported a position in AVDL in Q1 2024 and held it in 3 quarters. The position peaked at $16.9M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 782,239 Avadel Pharmaceuticals shares in Q1 2026, an estimated $16.9M.
  • Hudson Bay Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2024 and held it in 3 quarters.
  • Hudson Bay Capital Management's Avadel Pharmaceuticals position peaked at $16.9M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.